Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) have earned an average recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $68.00.
Several research analysts have commented on SWTX shares. Wedbush increased their price objective on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, February 26th. JPMorgan Chase & Co. increased their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright increased their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Barclays upped their price target on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Guggenheim began coverage on shares of SpringWorks Therapeutics in a research note on Monday, February 5th. They set a “buy” rating and a $75.00 price objective for the company.
View Our Latest Report on SWTX
Insider Activity at SpringWorks Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of SWTX. TD Asset Management Inc raised its holdings in SpringWorks Therapeutics by 122.1% in the 3rd quarter. TD Asset Management Inc now owns 138,832 shares of the company’s stock worth $3,210,000 after acquiring an additional 76,316 shares during the period. Assetmark Inc. raised its holdings in SpringWorks Therapeutics by 15.6% in the 3rd quarter. Assetmark Inc. now owns 10,814 shares of the company’s stock worth $250,000 after acquiring an additional 1,461 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of SpringWorks Therapeutics by 7.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 33,260 shares of the company’s stock worth $769,000 after purchasing an additional 2,400 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company’s stock worth $37,000 after purchasing an additional 792 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in shares of SpringWorks Therapeutics by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 9,770 shares of the company’s stock worth $226,000 after purchasing an additional 441 shares during the period.
SpringWorks Therapeutics Trading Down 1.4 %
Shares of SWTX opened at $43.38 on Friday. The firm has a market cap of $3.20 billion, a PE ratio of -8.44 and a beta of 0.83. SpringWorks Therapeutics has a 1-year low of $18.00 and a 1-year high of $53.92. The firm has a fifty day simple moving average of $47.83 and a two-hundred day simple moving average of $37.56.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The firm had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period last year, the business earned ($1.19) EPS. As a group, research analysts forecast that SpringWorks Therapeutics will post -4.71 EPS for the current fiscal year.
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Featured Articles
- Five stocks we like better than SpringWorks Therapeutics
- Investing in the High PE Growth Stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- Trading Halts Explained
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Health Care Stocks Explained: Why You Might Want to Invest
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.